These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23591198)

  • 1. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
    Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
    Usul Afsar Ç; Karabulut M; Karabulut S; Alis H; Gonenc M; Dagoglu N; Serilmez M; Tas F
    J Infect Chemother; 2017 Apr; 23(4):196-200. PubMed ID: 28087305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
    Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
    Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
    J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Wilkowski R; Bruns CJ; Issels RD; Schulz C; Moosmann N; Laessig D; Haas M; Golf A; Heinemann V
    Oncology; 2007; 73(3-4):221-7. PubMed ID: 18424886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
    Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
    Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
    Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
    Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
    Brody JR; Witkiewicz AK; Yeo CJ
    Adv Surg; 2011; 45():301-21. PubMed ID: 21954696
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
    O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
    Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
    Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
    Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
    Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
    Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
    Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.